Target intelligence / Profile preview

CDKN1A interacting zinc finger protein 1 (CIZ1)

Target
CIZ1
Molecular classification
Zinc finger DNA binding protein, Nuclear matrix protein, Transcription factor, RNA-binding protein
01

Overview

CDKN1A interacting zinc finger protein 1 (CIZ1) is a nuclear protein that interacts with p21 (CIP1/CDKN1A) and cyclin E, playing a key regulatory role in coordinating DNA replication and cell cycle progression at the G1/S transition. CIZ1 is anchored to the nuclear matrix and forms assemblies in specific replication foci, ensuring proper initiation of DNA synthesis. It also is essential for maintenance phase of X chromosome inactivation, binding directly to Xist long noncoding RNA via intrinsically disordered domains and thereby supporting epigenetic silencing in female cells. CIZ1's function extends to chromatin organization, and its deregulation—via mutation, alternative splicing, or abnormal expression—is implicated in a variety of human diseases, particularly cancers (where alternative circulating forms serve as potential biomarkers), neurological disorders (including dystonia and cognitive decline), and lymphoproliferative disease. Its multifunctional nature and role in pathological states make it a candidate novel therapeutic target for future investigation.

Other names
Cip1-interacting zinc finger proteinLSFR1NP94ZNF356CDKN1A-interacting zinc finger protein 1Nuclear protein NP94Zinc finger protein 356
02

Mechanism of action

Not directly targeted by clinical drugs yet; theorized mechanisms may include blockade of its interaction with cell cycle proteins (e.g., p21/CIP1 or cyclin E), modulation of its RNA-binding capacity, or inhibition of its assembly formation in chromatin regulation

03

Biological functions

DNA replication coordinationCell cycle progression (G1/S transition)Chromatin organizationEpigenetic silencing (X chromosome inactivation)Protein–RNA assembly formationRegulation of cell proliferationCell-cycle checkpoint regulation
04

Disease associations

Cancer (especially lung cancer and others linked to abnormal CIZ1 expression/splicing)Neurodegenerative disease (dystonia, cognitive decline)Lymphoproliferative disorder (sex-specific in mice)Other (possible roles in abnormal cell cycle regulation, apoptosis)
05

Safety considerations

No clinical drugs directly targeting CIZ1 are approved, but notable challenges for future therapeutics may include potential off-target effects on DNA replication and cell cycle, and interference with chromatin organization and X chromosome inactivation, risking genomic instability
06

Interacting drugs

None directly known or clinically validated as of current literature; CIZ1 is considered a potential target, especially for cancer diagnostics and therapeutics, but no interacting small molecules or drugs are established
07

Biomarkers

Circulating CIZ1 protein variants as noninvasive biomarkers for early-stage lung cancerAberrant CIZ1 splicing or overexpression in cancers as diagnostic/prognostic biomarkers

Beyond the preview

Go deeper on CDKN1A interacting zinc finger protein 1 (CIZ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDKN1A interacting zinc finger protein 1 (CIZ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call